UK Edition. Click here for US version.
CURTEGA 10 MG/ML EMULSION FOR INJECTION/INFUSION
Active substance(s): PROPOFOL / PROPOFOL / PROPOFOL
Curtega 10mg/ml Emulsion for injection/infusion
Read all of this leaflet carefully before you are given this medicine.
• Keep this leaflet. You may need to read it again.
• If you have any further questions, ask your doctor/nurse or pharmacist.
• This medicine has been prescribed for you. Do not pass it on to others. It may harm
them, even if their symptoms are the same as yours.
• If any of the side effects gets serious, or if you notice any side effects not listed in this
leaflet, please tell your doctor/ nurse or pharmacist.
In this leaflet:
1. What Curtega is and what it is used for
2. Before you are given Curtega
3. How you are given Curtega
4. Possible side effects
5. How to store Curtega
6. Further information.
WHAT CURTEGA IS AND WHAT IT IS USED FOR
Propofol belongs to a group of medicines called general anaesthetics. General
anaesthetics are used to cause unconsciousness (sleep) so that surgical operations or other
procedures can be performed. They can also be used to sedate you (so that you are sleepy
but not completely asleep).
Curtega 10 mg/ml is used to:
• induce and maintain general anaesthesia in adults and children >1 month
• sedate patients > 16 years of age receiving artificial respiration in intensive care
• sedate adults and children > 1 month during diagnostic and surgical procedures, alone
or in combination with local or regional anaesthesia.
2. BEFORE YOU ARE GIVEN CURTEGA
Do not use Curtega:
- in patients allergic (hypersensitive) to propofol or any of the other ingredients
- in patients allergic (hypersensitive) to soya or peanut
- in patients 16 years of age or younger for sedation in intensive care.
Take special care with Curtega
You should take Curtega, only under extreme caution and intensive monitoring, if you:
have advanced heart failure
have any other serious disease of the heart
The use of Curtega is not recommended if you are receiving electroconvulsive therapy
(ECT, a treatment for psychiatric problems).
The use of Curtega 10 mg/ml is not recommended in newborn infants.
Special care should also be observed when administering Curtega to children less than 3
years of age. However, evidence now available does not suggest that this is any less safe
than in older children. The safety of propofol for sedation in children and adolescents 16
years of age and younger in the intensive care unit has not been demonstrated.
In general, Curtega should be given with caution to elderly or weak patients.
Before receiving Curtega, tell your anaesthetist or intensive care doctor if you have:
- heart disease
- lung disease
- kidney disease
- liver disease
- seizures (epilepsy)
- a raised pressure inside the skull (raised intracranial pressure). In combination with
low blood pressure the amount of blood reaching the brain may be decreased
- altered levels of fat in the blood. If you receiving total parenteral nutrition (feeding
through a vein), the levels of fat in your blood must be monitored.
- had alcohol
- sensitivity to sodium
If you have any of the following conditions, they must be treated before you receive
- heart failure
- when there is insufficient blood reaching the tissues (circulatory failure)
- severe breathing problems (respiratory failure)
- dehydration (hypovolaemia)
- seizures (epilepsy)
Curtega may increase the risk of
- epileptic seizures
- a nervous reflex that slows the heart rate (vagotonia, bradycardia)
- changes in the blood flow to the organs of the body (haemodynamic effects on the
cardiovascular system) if you are overweight and receive high doses of Curtega
Involuntary movements can occur during sedation with Curtega. The doctors will take
into account how this might affect surgical procedures being performed under sedation
and will take the necessary precautions.
Very occasionally, after anaesthesia, there may be a period of unconsciousness associated
with stiffness of the muscles. This requires observation by the medical staff but no other
treatment. It will resolve spontaneously.
The injection of Curtega can be painful. A local anaesthetic can be used to reduce this
pain but can have its own side effects.
You will not be allowed to leave the hospital until you are fully awake.
Taking other medicines
Please tell your doctor if you are taking or have recently taken any other medicines,
including medicines obtained without a prescription. This includes medicines, herbal
remedies, health foods or supplements that you have bought yourself.
You must take special care if you are also taking any of the following medicines:
• premedications (your anaesthetist will know this)
• analgesics (painkillers), e.g. fentanyl
• drugs that relax muscles, e.g. suxamethonium
• benzodiazepines (drugs for anxiety), e.g. diazepam
• parasympatholytic drugs (drugs that effect everyday activities such as salivation,
digestion, and muscle relaxation, e.g. atropine)
• neostigmine (a treatment for muscle weakness)
• cyclosporin (used to prevent rejection of an organ)
Using Curtega with food and drink
Alcohol and propofol make the sedative effects of each other stronger. Therefore you
should not drink alcohol just before or just after you have Curtega until fully recovered.
Pregnancy and breast-feeding
Curtega should not be given to pregnant women unless clearly necessary. If you are
breast-feeding your child you should stop nursing and discard breast milk for 24 hours
after you have received Curtega. Curtega is excreted in small amounts into the breast
Driving and using machines
After you have been given Curtega, you must not drive, operate machinery, or work in
dangerous situations. You should not go home alone and should not drink alcohol until
Important information about some of the ingredients in Curtega
Curtega contains soya-bean oil. If you are allergic to peanut or soya, do not use this
This medicinal product contains less than 1 mmol sodium (23 mg) sodium i. e. essentially
3. HOW YOU ARE GIVEN CURTEGA
Curtega will be given to you by your anaesthetist or intensive care doctor.
The amount of Curtega you need depends on your age, size, fitness and the level of
sleepiness or sleep that is needed. The doctor will give the correct dose to start and to
sustain anaesthesia or to achieve the required level of sedation, by carefully watching
your responses and vital signs (pulse, blood pressure, breathing, etc). It can also be
affected by other medicines you may be taking. Most people need 1.5-2.5 mg per kg of
body weight to make them sleepy or to put them to sleep, and then 4 to 12 mg/kg (body
weight)/hour after this. For sedation, doses of 0.3 to 4.0 mg propofol per kg body weight
per hour are usually sufficient.
For sedation during surgical and diagnostic procedures in adults, most patients will
require 0.5 - 1 mg propofol per kg body weight over 1 to 5 minutes for onset of sedation.
Maintenance of sedation may be accomplished by titrating Curtega infusion to the desired
level of sedation. Most patients will require 1.5 - 4.5 mg propofol per kg body weight per
The infusion may be supplemented by bolus administration of 10 – 20 mg (1 – 2 ml
Curtega 10 mg/ ml if a rapid increase of the depth of sedation is required.
Curtega is given as an injection into a vein, usually on the back of the hand or in the
forearm. Your anaesthetist may use a needle or cannula (a fine plastic tube). An electric
pump may be used to give the injection for long operations and for use in intensive care.
Elderly and weak patients may require lower doses.
Children usually require slightly higher doses. The dose should be adjusted according to
age and/or body weight.
When used for sedation, Curtega must not be administered for more than 7 days.
If you received more Curtega than you should
It is unlikely that this occurs because the doses you receive are very carefully controlled.
If you are accidentally given an overdose, this could lead to depression of heart function,
circulation and breathing. In this case your doctor will employ any necessary treatment
If you have any further questions on the use of this product, ask your doctor or
4. POSSIBLE SIDE EFFECTS
Like all medicines, Curtega can cause side effects, although not everybody gets them.
Very common (affects more than 1 user in 10)
- Local pain during the injection
Common (affects 1 to 10 users in 100)
- low blood pressure (hypotension)
- shallow breathing (respiratory depression)
- spontaneous movements
- slow heartbeat (bradycardia)
- hot flushes
- temporary apnoea (stopping breathing)
- coughing after anaesthesia
- hiccups (singultus)
- hyperventilation (increased breathing)
Uncommon (affects 1 to 10 users in 1,000)
- severe low blood pressure (hypotension)
- slow heartbeat (bradycardia)
- coughing during anaesthesia
Rare (affects 1 to 10 users in 10,000)
- anaphylaxis (a severe allergic reaction)
- euphoria (feeling happy) and sexually aroused during recovery
- vertigo (spinning dizziness)
- shivering and sensations of cold during the recovery period
- epileptiform movements (resembling epilepsy)
- irregular heartbeat (arrhythmia) during recovery
- blood clots (thrombosis) and inflammation of the blood vessels (phlebitis)
- coughing during recovery
- feeling sick (nausea) or vomiting during recovery
- discoloration of urine
- post-operative fever
- red inflammation of the skin (erythema)
- low blood pressure (hypotension)
- bronchospasm (a condition that causes difficulty in breathing)
- angioneurotic oedema (Quincke's disease)
Very rare (affects less than 1 user in 10,000)
- delayed epileptiform attacks (epilepsy like symptoms after recovery)
- convulsions in epileptic patients
- unconsciousness after anaesthesia
- fluid in the lungs (pulmonary oedema)
- inflammation of the pancreas (pancreatitis)
- severe tissue responses after accidental injection into tissues
- rhabdomyolysis (breakdown of muscle fibres)
- metabolic acidosis (acidic blood)
- high blood potassium (hyperkalaemia)
- heart (cardiac) failure
When Curtega is administered in combination with lidocaine (a local anaesthetic used to
reduce the pain at the site of injection), certain side effects may occur rarely:
- a slowing of the heart rate (bradycardia)
- irregular heartbeat (cardiac arrhythmias)
If any of the side effects gets serious, or if you notice any side effects not listed in this
leaflet, please tell your doctor or pharmacist.
5. HOW TO STORE CURTEGA
Keep out of the reach and sight of children.
Do not use Curtega after the expiry date, which is stated on the vial/bottle and the outer
carton after “EXP.” The expiry date refers to the last day of that month.
Do not store above 25º C. Do not freeze.
Store in the original carton in order to protect from light.
After opening the product must be used immediately.
Shake before use.
Curtega can be diluted with solutions of glucose 5%, sodium chloride 0.9 % or
combinations of 4% glucose and 0.18% sodium chloride.
The maximum dilution should not exceed 1 part Curtega 10 mg/ml for 4 parts of the
solutions mentioned above (minimal concentration 2 mg / ml). Furthermore Curtega can
be mixed with a lidocaine 1 % solution for injection without preservatives. One part
lidocaine solution for injection should then be mixed with 20 parts Curtega 10 mg/ml.
The mixtures should be prepared aseptically immediately before administration.
Solutions in glass bottles or PVC bags can both be used, as long as they are well mixed
prior to administration.
The simultaneous administration of Curtega 10 mg/ml together with an infusion of 5%
glucose, 0.9% sodium chloride or combinations of 4% glucose with a 0.18% sodium
chloride solution close to the Y-connector near the place of injection, is also possible.
For single use only. Any unused product or waste material should be disposed of in
accordance with local requirements, immediately after use.
6. FURTHER INFORMATION
What Curtega contains
The active substance is propofol.
Each ml of emulsion for injection/infusion contains 10 mg of propofol.
Each 10 ml vial contains 100 mg propofol
Each 20 ml vial contains 200 mg propofol
Each 50 ml vial contains 500 mg propofol
Each 100 ml vial contains 1000 mg propofol.
The other ingredients are: soybean oil refined, egg lecithin, glycerol, sodium oleate,
sodium hydroxide (for pH adjustment) and water for injections.
What Curtega looks like and the content of the pack
White oil in water emulsion. Package with one glass vial (type II) with bromobutyl
rubber stopper and plastic cap containing 10 ml, 20 ml, 50 ml or 100 ml emulsion for
Not all pack sizes may be marketed.
Marketing Authorisation Holder and Manufacturer
This medicinal product is authorized in the Member States of EEA under the following
This leaflet was last approved in 06/2011
The following information is intended for medical or healthcare professionals only:
Curtega 10 mg/ml can only be administered in hospitals or well equipped units by doctors
who are trained in anaesthesia or the treatment of intensive care patients.
Curtega must not be used in patients allergic to soya or peanuts.
Continuous surveillance of circulation and breathing (e.g. ECG, pulse oxymeter) is
necessary. Facilities for maintenance of patient airways, artificial ventilation and other
resuscitation facilities should be available immediately and at all times.
During surgical or diagnostic procedures Curtega 10 mg/ml should not be administered
for sedation by the same person who executes the surgical or diagnostic intervention.
Containers should be shaken before use. If two layers can be seen after shaking, the
emulsion should not be used.
Before using, the rubber stopper of the infusion vial must be disinfected with medicinal
alcohol (spray or tissues). After use anything remaining should be discarded.
Curtega 10 mg/ml does not contain preservatives and is capable of supporting the growth
of micro-organisms. The emulsion should immediately be drawn, aseptically, in a sterile
syringe or the infusion system, after spiking the vial.
Administration should commence immediately afterwards. During the infusion the
sterility of Curtega 10 mg/ml as well as the infusion system needs to be maintained.
Medicines or liquids that are added to a running Curtega 10 mg/ml infusion should be
added close to the cannula. Curtega 10 mg/ml should not be administered via infusion
systems that are provided with microbial filters.
The contents of one vial with Curtega 10 mg/ml and every syringe of Curtega 10 mg/ml
is intended for single use for one patient.
The remainder must be discarded immediately after use.
Infusion of undiluted Curtega 10 mg/ml
When Curtega 10 mg/ml is administered through a continuous infusion, checking the rate
of infusion through a burette, dropper, syringe pump or volumetric infusion pump is
recommended. As applies to parenteral administration of all kinds of fat emulsions, the
duration of use for one infusion system for a continuous infusion of Curtega 10mg/ml
should be limited to maximum 12 hours. The infusion system and the container should be
removed and changed after maximum 12 hours.
The simultaneous administration of Curtega 10 mg/ml together with an infusion of 5%
glucose, 0.9% sodium chloride or combinations of 4% glucose with 0.18% sodium
chloride solutions close to the Y-connector near the place of injection, is possible.
Any Curtega 10 mg/ml remaining at the end of the infusion period or after changing the
system needs to be discarded and destroyed.
Infusion of diluted Curtega 10 mg/ml
When Curtega 10 mg/ml is administered diluted through a continuous infusion, the
checking of the rate of administration by means of a burette, dropper, syringe pump or
volumetric infusion pump is recommended, to prevent the accidental administration of
too high doses of diluted Curtega 10 mg/ml.
Curtega 10 mg/ml must not be mixed with other injection or infusion liquids other than
the ones mentioned.
To lessen the pain at the start of the injection, Curtega 10 mg/ml can be mixed with a
lidocaine 1% solution for injection without preservatives.
Dilutions with a lidocaine solution should not be administered to patients with a
hereditary predisposition to acute porphyria.
The neuromuscular blocking agents, atracurium and mivacurium should not be given
through the same intravenous line as Curtega 10 mg/ml without prior flushing.
Source: Medicines and Healthcare Products Regulatory Agency
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.